Interaction between maternal hyperglycaemia in pregnancy and periods (pre-IADPSG and post-IADPSG) on several neonatal outcomes
| Outcomes | P-value for interaction*† |
| Hospital death | 0.61 |
| RDS | 0.1 |
| NEC | 0.88 |
| PDA required any treatment | 0.68 |
| IVH or PVL | 0.19 |
| CLD 28 | 0.61 |
| ROP required any treatment | 0.12 |
| Composite‡ | 0.80 |
*Calculated using multivariate logistic regression analysis with adjustment for maternal age, parity, mode of delivery, sex, antenatal steroid use, gestational week, SGA, Apgar score at 5 min.
†P value for interaction <0.1 is considered significant.
‡Includes hospital death, NEC, PDA required any treatment, IVH or PVL, CLD 36 and ROP requiring any treatment.
CLD, chronic lung disease; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP, retinopathy of prematurity.